Skip to content

8:00 am Chair’s Opening Remarks

  • Ross Jeggo Head of Neuroscience Research, Servier

The Neurodegenerative Drug Development State of Mind: Challenging Traditional Thinking for Promising Future Development

8:15 am Neuroscience at the Inflection Point: Great News for Patients

8:45 am The Evolving Landscape of Outsourcing Preclinical Research in Parkinson’s Disease: A CRO’s Perspective

9:15 am Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

9:45 am Speed Networking

10:15 am Morning Refreshments

Innovation Stream

Translational Stream

Emerging Targets for Neurodegeneration: New Prospects

Optimizing the Value Provided by Preclinical Models for Improved Clinical Predictions

11.30 Choosing the Right Target: Using Human Genetics and Biology for Target Identification and Validation.

Will Chen, Senior Director, Translational Biology, Biogen

 

12.00 The Gut-Brain Axis in CNS diseases

David Donabedian, Chief Executive Officer, Axial Therapeutics

 

12.30 A Neuroimmunology Perspective on Target Validation in Alzheimer’s Disease

Alison Mungenast, Principal Scientist & Neuroscience Lead, Eisai

 

1.00 Panel Discussion: Exploring Future Targets for Neurodegenerative Disease

Will Chen, Senior Director, Translational Biology, Biogen

David Donabedian, Chief Executive Officer, Axial Therapeutics

Alison Mungenast, Principal Scientist & Neuroscience Lead, Eisai

11.30 Interpreting the Data Provided by Animal Models for Optimal Drug Development – PK & PD Opportunities

Johan Luthman, Executive Vice President & Head of Research & Development, Lundbeck

 

12.00 The Promise of Human iPSC-based Models to Advance the Discovery of Therapies for Neurodegenerative Diseases

Sophie Parmentier-Batteur, Director, Neuroscience Discovery, Merck Research Laboratories

 

12.30 Seeking Improved Brain Shuttles Using Novel Endothelial ‘Omics & Human In Vitro Assays

James Gorman, Brain Targeting Program, Wyss Institute for Biologically Inspired Engineering, Harvard

 

1.00 Preclinical Model Audience Discussion

Amy Easton, Senior Scientific Manager, Drug Discovery, Genentech

 

1:30 pm Lunch & Networking

Exploring Gene Therapy as a Therapeutic
for Neurodegeneration

Innovating Biomarker Discovery to Transform Neurodegenerative Drug Development

2.30 Reviewing the Clinical Progress in Gene Therapies for Neurodegeneration

Oliver Danos, Chief Scientific Officer, REGENXBIO

 

3.00 Assessing the Challenges of Gene Therapy: Delivery, Specificity & Safety

Lamya Shihabuddin, Head of Genetic Neurologic Diseases, Sanofi

 

3.30 Panel Discussion: Debating the Pros & Cons of Gene Therapy

Lamya Shihabuddin, Head of Genetic Neurologic Diseases, Sanofi

Oliver Danos, Chief Scientific Officer, REGENXBIO

 

4.00 Extended Q&A

2.30 Introducing Digital Biomarkers to Stratify Patient Populations & Analyse Disease Progression 

Sheraz Khan, Director of the Khan Lab, Harvard, MGH & MIT

 

3.00 Popular Microglial Target: Efficient, Robust Characterization of Microglial States

Bob Switzer, Founder, President & Chief Scientific Officer, NeuroScience Associates

 

3.30 Path to Target-Specific Biomarker Discovery

Pascal Sanchez, Director, Translational Sciences, Denali Therapeutics

 

4.00 Audience Discussion: Biomarkers of Neurodegeneration

4:30 pm Afternoon Refreshments & Networking

Transforming Clinical Success in Neurodegenerative Drug Development

5:30 pm Don’t Enter the Clinic Without a Pilot Study

  • Michael Gold Vice President, Neuroscience Development, AbbVie

6:00 pm Transforming Neurodegenerative Drug Development with State-ofthe-Art Technology

  • Eric Schaeffer Senior Director, Neuroscience Innovation, Janssen
  • Richard Hargreaves Vice President, Head Neuroscience & Imaging Research & Early Development, Celgene
  • Ross Jeggo Head of Neuroscience Research, Servier

6:30 pm Quick-Fire Poster Presentation Talks

7:00 pm Chair’s Closing Remarks

  • Ross Jeggo Head of Neuroscience Research, Servier

7:15 pm Scientific Poster Session